

# Edwards AMC Thromboshield Treatment

The only coating to provide both antimicrobial\*  
and thromboresistant protection

**AMC Thromboshield treatment is available on  
a wide variety of critical care products including:**

- Edwards Multi-Med Central Venous Infusion Catheters
- Edwards IntroFlex Percutaneous Sheath Introducers
- Edwards Swan-Ganz Catheters
- Edwards Vantex Central Venous Catheters
- Edwards AVA 3Xi Device
- Edwards AVA High-Flow Device


## **Infection Control with Double Protection.**

Edwards AMC Thromboshield treatment is an exclusive combination of benzalkonium chloride with heparin coating as a double-safeguard both inside and out.


- Benzalkonium chloride provides antimicrobial protection against commonly encountered organisms.<sup>1</sup>
- Heparin reduces thrombus formation, where microorganisms can colonize and lead to catheter-related infections.
- AMC Thromboshield treatment is applied to the entire surface of the catheter, both inside and outside. This is a significant advantage over catheters with protection only on the outside, as contamination can lead to infection in the inner lumen resulting in catheter-related sepsis.




**Edwards**  
LIFESCIENCES




AMC Thromboshield inhibits the most common bacteria and yeasts found on catheters\*\*<sup>1</sup>



AMC Thromboshield reduces *S. epidermidis* bacteria levels on the catheter surface by a factor of nearly 100. CFU = Colony Forming Units



AMC Thromboshield consistently retards bacterial growth at various locations along the catheter body. CFU = Colony Forming Units<sup>2</sup>



AMC Thromboshield provides a zone of inhibition all along the catheter body.

## Proven Results.

- The antimicrobial benefits of AMC Thromboshield treatment are demonstrated in *in vitro* studies.
- Laboratory tests show that its antimicrobial power can lead to a 110x reduction in microorganisms commonly associated with catheter-related nosocomial infections.
- AMC Thromboshield treatment showed significant (1.9 log<sub>10</sub>) reduction in bacteria (*in vitro* study).

\*Significant antimicrobial activity associated with AMC Thromboshield treatment has been demonstrated using *in vitro* agar diffusion assays against the following organisms: *Staphylococcus epidermidis*, *Staphylococcus aureus*, *Streptococcus faecalis*, *Candida albicans*, *Escherichia coli*, *Serratia marcescens*, and *Acinetobacter calcoaceticus*.

\*\**In vitro* testing of agar diffusion assays on "seeded" Tryptic Soy Agar plates show that the spectrum of AMC Thromboshield treatment activity is centered on *S. epidermidis*, the most common bacteria implicated in intravascular catheter sepsis. The microorganisms tested are representative of the most common bacteria and yeasts isolated from infected catheters.

### Legend

<sup>1</sup> Sa: *S. aureus*  
 Se: *S. epidermidis*  
 Sf: *S. faecalis*  
 Ec: *E. coli*  
 Sm: *S. marcescens*

### <sup>2</sup> Catheter Segment Location *In Situ*

Location 1 = Distal Tip;  
 6 = Proximal to Insertion Site

Haslett TM, et al. *Microbiology of indwelling central intravascular catheters*. J Clin Microbiol 1988; 26(4): 696-701.

Data on file at Edwards Lifesciences.

Elliott TSJ. *Intravascular-device infections*. J Med Microbiol 1988; 27: 161-167.

Mermel LA, et al. *Surface antimicrobial activity of heparin-bonded and antiseptic-impregnated vascular catheters*. JID 1993; 167: 920-924.



Refer to the current product package insert for indications, contraindications, warnings and instructions for use.

Edwards Lifesciences, Edwards, the stylized E logo and AVA High-Flow are trademarks of Edwards Lifesciences Corporation. AMC Thromboshield, AVA 3Xi, IntroFlex, Multi-Med, Swan-Ganz and Vantex are trademarks of Edwards Lifesciences Corporation and are registered in the US Patent and Trademarks Office.

© 2003 Edwards Lifesciences LLC. All rights reserved. Printed in U.S.A. AR00168



# Edwards Lifesciences